ANIX - CIK 0000715446
Anixa Biosciences Inc (ANIX) reported net income of -$10.93M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$10.93M | +13.0% |
| FY 2024 | -$12.55M | -28.0% |
| FY 2023 | -$9.81M | +27.8% |
| FY 2022 | -$13.60M | -4.9% |
| FY 2021 | -$12.95M | -29.3% |
| FY 2020 | -$10.02M | +14.0% |
| FY 2019 | -$11.65M | +16.8% |
| FY 2018 | -$14.00M | -179.4% |
| FY 2017 |
Anixa Biosciences Inc (ANIX) reported net income of -$10.93M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Anixa Biosciences Inc's net income declined from -$7.38M to -$10.93M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$5.01M |
| +0.1% |
| FY 2016 | -$5.02M | -263.8% |
| FY 2015 | -$1.38M | +85.6% |
| FY 2014 | -$9.61M | +4.7% |
| FY 2013 | -$10.08M | -137.0% |
| FY 2012 | -$4.25M | +42.4% |
| FY 2011 | -$7.38M | - |